mAb-话题@MedSci

#mAb#

1302篇内容 | 2241人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912503, encodeId=fb6a1912503b2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准, objectType=article, longId=204985, objectId=cbfa20498514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbfa20498514, replyNumber=0, likeNumber=80, createdTime=2021-10-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbfa20498514, moduleTitle=埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbfa20498514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912450, encodeId=4b181912450da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）, objectType=article, longId=201574, objectId=8f992015e4ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f992015e4ca, replyNumber=0, likeNumber=52, createdTime=2021-09-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f992015e4ca, moduleTitle=欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f992015e4ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912588, encodeId=7e25191258890, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, objectType=article, longId=210410, objectId=eb7421041030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7421041030, replyNumber=0, likeNumber=99, createdTime=2021-04-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7421041030, moduleTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7421041030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912637, encodeId=31b9191263e1f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=56, createdTime=2021-11-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912427, encodeId=7725191242eef, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, objectType=article, longId=199475, objectId=ce771994e50b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce771994e50b, replyNumber=0, likeNumber=58, createdTime=2020-12-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce771994e50b, moduleTitle=Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce771994e50b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912510, encodeId=8a4d1912510ac, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Tocilizumab和sarilumab降低了COVID-19重症患者的死亡风险, objectType=article, longId=205521, objectId=fbd9205521cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbd9205521cd, replyNumber=0, likeNumber=124, createdTime=2021-10-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbd9205521cd, moduleTitle=Tocilizumab和sarilumab降低了COVID-19重症患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbd9205521cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912590, encodeId=2eef1912590d7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, objectType=article, longId=210420, objectId=5536210420a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5536210420a0, replyNumber=0, likeNumber=127, createdTime=2021-07-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5536210420a0, moduleTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5536210420a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912475, encodeId=ec7819124e5b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Itolizumab治疗急性移植物抗宿主病（aGVHD），已取得阳性中期数据, objectType=article, longId=203076, objectId=1a392030e64f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a392030e64f, replyNumber=0, likeNumber=89, createdTime=2021-03-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a392030e64f, moduleTitle=Itolizumab治疗急性移植物抗宿主病（aGVHD），已取得阳性中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a392030e64f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912430, encodeId=3c6b191243005, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性, objectType=article, longId=199626, objectId=d462199626d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d462199626d8, replyNumber=0, likeNumber=52, createdTime=2021-07-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d462199626d8, moduleTitle=J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d462199626d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912541, encodeId=a6be19125415a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=视力下降疗法Faricimab将两次治疗之间的时间延长了四个月, objectType=article, longId=207134, objectId=230c20e13403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=230c20e13403, replyNumber=0, likeNumber=62, createdTime=2021-04-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=230c20e13403, moduleTitle=视力下降疗法Faricimab将两次治疗之间的时间延长了四个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=230c20e13403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912429, encodeId=c72f1912429e2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Rheumatol：重症监护室的COVID-19患者采用Tocilizumab治疗对预后的影响, objectType=article, longId=199607, objectId=d59219960ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d59219960ede, replyNumber=0, likeNumber=112, createdTime=2021-06-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d59219960ede, moduleTitle=Lancet Rheumatol：重症监护室的COVID-19患者采用Tocilizumab治疗对预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d59219960ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912554, encodeId=e7471912554a7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, objectType=article, longId=207705, objectId=73c620e7058a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c620e7058a, replyNumber=0, likeNumber=114, createdTime=2021-04-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c620e7058a, moduleTitle=CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c620e7058a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912500, encodeId=484d191250019, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, objectType=article, longId=204612, objectId=b76e204612db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b76e204612db, replyNumber=0, likeNumber=57, createdTime=2021-07-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b76e204612db, moduleTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b76e204612db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912477, encodeId=681219124e72c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, objectType=article, longId=203134, objectId=b12e2031349b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12e2031349b, replyNumber=0, likeNumber=63, createdTime=2021-05-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12e2031349b, moduleTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12e2031349b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912626, encodeId=71091912626a2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, objectType=article, longId=212817, objectId=1b8121281e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8121281e7b, replyNumber=0, likeNumber=111, createdTime=2021-07-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8121281e7b, moduleTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8121281e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912442, encodeId=97a9191244248, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, objectType=article, longId=201131, objectId=a81a2011316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81a2011316b, replyNumber=0, likeNumber=91, createdTime=2021-07-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81a2011316b, moduleTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a81a2011316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912489, encodeId=5a87191248914, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：III期 | 一线诱导化疗后Avelumab维持治疗对晚期胃癌患者预后的作用, objectType=article, longId=203571, objectId=92742035e184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92742035e184, replyNumber=0, likeNumber=71, createdTime=2021-09-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92742035e184, moduleTitle=J Clin Oncol：III期 | 一线诱导化疗后Avelumab维持治疗对晚期胃癌患者预后的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92742035e184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912501, encodeId=94321912501c8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=礼来公司在新墨西哥州开始对COVID-19中和抗体bamlanivimab（LY-CoV555）进行研究, objectType=article, longId=204704, objectId=d576204e0481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d576204e0481, replyNumber=0, likeNumber=50, createdTime=2021-01-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d576204e0481, moduleTitle=礼来公司在新墨西哥州开始对COVID-19中和抗体bamlanivimab（LY-CoV555）进行研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d576204e0481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912508, encodeId=60ba19125089a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, objectType=article, longId=205265, objectId=52e920526519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52e920526519, replyNumber=0, likeNumber=144, createdTime=2021-02-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52e920526519, moduleTitle=Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52e920526519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912569, encodeId=191d1912569b3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, objectType=article, longId=208673, objectId=25e82086e3fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25e82086e3fe, replyNumber=0, likeNumber=105, createdTime=2021-04-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25e82086e3fe, moduleTitle=NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25e82086e3fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准

2021-10-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

欧洲委员会（EC）批准CRYSVITA（burosumab）治疗老年人和成年人X连锁性低磷血症（XLH）

2021-09-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌

2021-04-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-11-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：Avelumab治疗复发性/难治性结外NK/T细胞淋巴瘤

2020-12-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Tocilizumab和sarilumab降低了COVID-19重症患者的死亡风险

2021-10-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病

2021-07-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Itolizumab治疗急性移植物抗宿主病（aGVHD），已取得阳性中期数据

2021-03-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Invest Dermatol：Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性

2021-07-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

视力下降疗法Faricimab将两次治疗之间的时间延长了四个月

2021-04-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Rheumatol：重症监护室的COVID-19患者采用Tocilizumab治疗对预后的影响

2021-06-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

CHMP建议批准Sarclisa（isatuximab）与卡非佐米和地塞米松联合治疗复发性多发性骨髓瘤

2021-04-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验

2021-07-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状

2021-05-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！

2021-07-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌

2021-07-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：III期 | 一线诱导化疗后Avelumab维持治疗对晚期胃癌患者预后的作用

2021-09-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

礼来公司在新墨西哥州开始对COVID-19中和抗体bamlanivimab（LY-CoV555）进行研究

2021-01-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncology| 广泛期小细胞肺癌一线Durvalumab联合治疗的效果比较

2021-02-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Pegcetacoplan对于阵发性睡眠性血红蛋白尿的治疗效果优于Eculizumab

2021-04-29

科室
- - 订阅+
  - 更多科室
工具
服务